Combination Metastasis-Targeted External Beam Radiation Therapy With 177Lu-PSMA-617 in Patients With Advanced Castration-Resistant Prostate Cancer
Practical Radiation Oncology · 2025-11 · 15 (6) · e597-e605
DOI: 10.1016/j.prro.2025.03.010 ↗Kurz gefasst
Fachartikel in der Zeitschrift Practical Radiation Oncology, 2025-11. Verfasst von Sedra Mohammadi und 14 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachu…. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Dipeptides, Heterocyclic Compounds, 1-Ring, Lutetium. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIDDK NIH HHS, NIBIB NIH HHS.
Abstract (Originalsprache)
PURPOSE: 177Lu-PSMA-617 (LuPSMA) is an effective radiopharmaceutical therapy for patients with metastatic castration-resistant prostate cancer. While LuPSMA can treat disseminated disease, additional localized control of metastatic disease may be required. Metastasis-targeted external beam radiation therapy (M-EBRT) can be an effective adjunct. However, the indications, efficacy, and safety/toxicity of combining M-EBRT with LuPSMA are unclear. Here, we report our experience with M-EBRT in patients receiving LuPSMA and assess M-EBRT's ability for local disease control and palliation. METHODS AND MATERIALS: This retrospective institutional review board-exempted study reviewed patients treated with LuPSMA at a multi-institutional academic cancer center within the first 2 years after United States Food and Drug Administration's approval, receiving contemporaneous M-EBRT. Clinical factors driving the use of M-EBRT were analyzed. RESULTS: Treatment courses of 261 patients receiving LuPSMA were reviewed; 52 patients received M-EBRT contemporaneously. M-EBRT was administered for intracranial/epidural disease (n = 22/52; 42%), bone pain palliation (n = 17/52; 33%), prevention of pathological fractures (n = 12/52; 23%), and 12% (n = 6/52) for various other indications. M-EBRT timing varied among patients, with 54% (n = 28/52) receiving M-EBRT before, 27% (n = 14/52) after, and 13% (n = 7/52) during LuPSMA therapy. EBRT was mostly well tolerated, although lymphopenia was commonly experienced. Most patients (n = 32/52; 62%) had symptom relief following M-EBRT. Symptom relief post-M-EBRT was 68%, 85%, and 50%, and mortality rates were 32%, 29%, and 57% for patients receiving EBRT before, during, and after LuPSMA treatment, respectively, albeit not statistically significant (P > .23). Prostate-specific antigen (PSA)50 (decrease in PSA by 50% during treatment) response in this patient population was 41% compared with 50% in the general LuPSMA population, but the magnitude of PSA response was heterogeneous (P = .27). CONCLUSIONS: In our experience, M-EBRT was used effectively with LuPSMA therapy for local tumor control and symptom management, especially for localized osseous and central nervous system lesions, and with good tolerability. M-EBRT may be an important adjunct treatment modality that facilitates the initiation and/or continuation of LuPSMA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
- Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
- Department of Medical Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
- Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
- Department of Radiation Oncology, Brigham and Women's Hospital/Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
- Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Förderung
- NCI NIH HHS
- NIDDK NIH HHS
- NIBIB NIH HHS
- US Department of Defense
- Lee Foundation
- National Institute of Biomedical Imaging and Bioengineering
- National Institutes of Health National Cancer Institute
- National Institutes of Health
Zitieren
APA
Mohammadi, S., Pompa, I. R., Haberman, V., Kako, B., Lee, R. J., Saylor, P. J., Gao, X., Esfahani, S. A., Heidari, P., Ravi, P., Sayan, M., Efstathiou, J. A., Jacene, H. A., Kamran, S. C., & Ng, T. S. C. (2025). Combination Metastasis-Targeted External Beam Radiation Therapy With 177Lu-PSMA-617 in Patients With Advanced Castration-Resistant Prostate Cancer. Practical Radiation Oncology, 15(6), e597-e605. https://doi.org/10.1016/j.prro.2025.03.010
Vancouver
Mohammadi S, Pompa IR, Haberman V, Kako B, Lee RJ, Saylor PJ, et al. Combination Metastasis-Targeted External Beam Radiation Therapy With 177Lu-PSMA-617 in Patients With Advanced Castration-Resistant Prostate Cancer. Practical Radiation Oncology. 2025;15(6):e597-e605. doi:10.1016/j.prro.2025.03.010
BibTeX
@article{Mohammadi2025,
author = {Mohammadi, Sedra and Pompa, Isabella R and Haberman, Veronica and Kako, Bashar and Lee, Richard J and Saylor, Philip J and Gao, Xin and Esfahani, Shadi A and Heidari, Pedram and Ravi, Praful and Sayan, Mutlay and Efstathiou, Jason A and Jacene, Heather A and Kamran, Sophia C and Ng, Thomas S C},
title = {Combination Metastasis-Targeted External Beam Radiation Therapy With 177Lu-PSMA-617 in Patients With Advanced Castration-Resistant Prostate Cancer},
journal = {Practical Radiation Oncology},
year = {2025},
volume = {15},
number = {6},
pages = {e597--e605},
doi = {10.1016/j.prro.2025.03.010}
}
EUVIMED